Cargando…

Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations

Detalles Bibliográficos
Autores principales:	Schüller, Ulrich, Iglauer, Peter, Dorostkar, Mario M., Mawrin, Christian, Herms, Jochen, Giese, Armin, Glatzel, Markus, Neumann, Julia E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847449/ https://www.ncbi.nlm.nih.gov/pubmed/33433639 http://dx.doi.org/10.1007/s00401-020-02259-y

Ejemplares similares

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman
por: Low, Justin Thomas, et al.
Publicado: (2021)

Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation
por: Miyazaki, Takeshi, et al.
Publicado: (2019)

Radiotherapy and radio‐sensitization in H3 (K27M) ‐mutated diffuse midline gliomas
por: Liu, Chao, et al.
Publicado: (2023)

Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas
por: Raab, Peter, et al.
Publicado: (2022)

Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation
por: Hassan, Usman, et al.
Publicado: (2021)

Diffuse midline glioma H3K27M mutation in adult: A case report
por: Bhattarai, Ayush Mohan, et al.
Publicado: (2022)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
por: Schreck, Karisa C., et al.
Publicado: (2019)

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

HGG-45. Characterization of spinal diffuse midline gliomas, H3 K28M-mutant
por: Stegat, Lotte, et al.
Publicado: (2022)

MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
por: Zhao, Ji-ping, et al.
Publicado: (2022)

Multimodal MR imaging signatures to identify brain diffuse midline gliomas with H3 K27M mutation
por: Su, Xiaorui, et al.
Publicado: (2021)

Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics
por: Li, Qian, et al.
Publicado: (2021)

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient
por: Cheng, Ran, et al.
Publicado: (2021)

Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma
por: López, Giselle, et al.
Publicado: (2017)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019)

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma
por: Immisch, Lena, et al.
Publicado: (2022)

Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report
por: Wang, Qiang, et al.
Publicado: (2021)

DIPG-78. REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
por: Nesvick, Cody, et al.
Publicado: (2020)

Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases
por: Zheng, Linmao, et al.
Publicado: (2022)

Diffuse midline glioma with H3-K27M mutation: A rare case with GFAP-positive anucleate whorled patterns
por: Wang, Yi-Hua, et al.
Publicado: (2022)

EXM 83-27
por: Malandain, E
Publicado: (1983)

Drug-sensitive FGFR3 mutations in lung adenocarcinoma
por: Chandrani, P., et al.
Publicado: (2017)

Identification of Radiomic Signatures in Brain MRI Sequences T1 and T2 That Differentiate Tumor Regions of Midline Gliomas with H3.3K27M Mutation
por: Chilaca-Rosas, Maria-Fatima, et al.
Publicado: (2023)

Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges
por: Himes, Benjamin T., et al.
Publicado: (2019)

Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study
por: Wang, Yuan, et al.
Publicado: (2021)

DIPG-38. Significant tumor regression of H3K27M-mutated diffuse midline glioma of the brainstem with panobinostat: a case report.
por: Partap, Sonia, et al.
Publicado: (2022)

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation
por: Rosty, Christophe, et al.
Publicado: (2005)

Mutational Status of FGFR3 in Oral Squamous Cell Carcinoma
por: Motahhary, P., et al.
Publicado: (2012)

Significance of the FGFR3 mutation in Chinese patients with bladder cancer
por: Hao, Lanxiang, et al.
Publicado: (2023)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
por: Chheda, Zinal S, et al.
Publicado: (2023)

Erratum to appendix 3 of CERN-PSCC-83-27-M-159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1983)

Diffuse midline glioma with novel, potentially targetable, FGFR2–VPS35 fusion
por: Zanazzi, George, et al.
Publicado: (2020)

Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas
por: On, Jotaro, et al.
Publicado: (2021)

Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures
por: Banan, Rouzbeh, et al.
Publicado: (2021)

Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease
por: Zou, Chengyu, et al.
Publicado: (2016)

Prevalence of Mutations in the FGFR3 Gene in Individuals with Idiopathic Short Stature
por: Mamada, Mitsukazu, et al.
Publicado: (2006)

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
por: Foth, Mona, et al.
Publicado: (2018)

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
por: Immisch, Lena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g6dlsrp2f9cgjk2ar6fn0rgin3